BVCF supports anti-viral drug innovation
Since the discovery of RNA interference (RNAi), a natural mechanism for regulating gene expression, in the 1990s, billions of dollars have been invested by the world’s pharmaceutical giants in using this technology to develop therapeutic drugs. A particular use is to inhibit the expression of pathogenic viruses, such as HIV and the Hepatitis B virus (HBV).
"There are still no effective therapies for curing diseases such as HIV and HBV, which are caused by viruses," Zhi Yang, founder and managing partner of China life science-focused firm BVCF, tells AVCJ....
More on Venture
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.